| Ms Kawanna Evette Ward, LCSW, CSAC, CSOTP | |
|
1634 London Blvd, Portsmouth, VA 23704-2137 | |
| (757) 966-1889 | |
| Not Available |
| Full Name | Ms Kawanna Evette Ward |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 24 Years |
| Location | 1634 London Blvd, Portsmouth, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043515331 | NPI | - | NPPES |
| Entity Name | Providence Psychological Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487090429 PECOS PAC ID: 8921242918 Enrollment ID: O20130912000531 |
News Archive
"This result is an encouraging step along the road to new tissues for patients to replace those that have failed or have been destroyed due to trauma or disease," she said.
Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.
A large study of intensive care patients in California found that public reporting of patient outcomes did not reduce mortality, but did result in reduced admission of the sickest patients to the ICU and increased transfer of critically ill patients to other hospitals.
Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.
› Verified 7 days ago
| Entity Name | Blakey Weaver Counseling Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245791995 PECOS PAC ID: 4284064981 Enrollment ID: O20200421001004 |
News Archive
"This result is an encouraging step along the road to new tissues for patients to replace those that have failed or have been destroyed due to trauma or disease," she said.
Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.
A large study of intensive care patients in California found that public reporting of patient outcomes did not reduce mortality, but did result in reduced admission of the sickest patients to the ICU and increased transfer of critically ill patients to other hospitals.
Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Kawanna Evette Ward, LCSW, CSAC, CSOTP 1634 London Blvd, Portsmouth, VA 23704-2137 Ph: (757) 966-1889 | Ms Kawanna Evette Ward, LCSW, CSAC, CSOTP 1634 London Blvd, Portsmouth, VA 23704-2137 Ph: (757) 966-1889 |
News Archive
"This result is an encouraging step along the road to new tissues for patients to replace those that have failed or have been destroyed due to trauma or disease," she said.
Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.
A large study of intensive care patients in California found that public reporting of patient outcomes did not reduce mortality, but did result in reduced admission of the sickest patients to the ICU and increased transfer of critically ill patients to other hospitals.
Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.
› Verified 7 days ago